U.S. drugmaker Pfizer Inc’s breast cancer drug, Ibrance, should be given marketing approval, an advisory committee at the European Medicines Agency recommended. The Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for Ibrance to be used in combination with two existing therapies in women who have ... Read More »